Lexicon Pharma shares jumped on Thursday morning after the company announced that it received regulatory feedback from the FDA regarding its heart failure treatment.
Arcturus Therapeutics shares took a tumble on Tuesday after the company announced update on its COVID-19 vaccine candidate.
Aprea Therapeutics stock was absolutely crushed to start out the week after the company announced results from its late-stage trial evaluating the safety and efficacy of its treatment for...
Myovant shares shot up on Monday after the company announced a new collaboration with Pfizer for its tumor treatment across a couple of indications.
Altimmune shares dropped on Thursday after the company announced that it had received an update from the FDA regarding its COVID-19 vaccine candidate.
Agios Pharmaceuticals shares jumped on Monday after the company announced that it will be streamlining its portfolio.
A new Stifel research report includes the firm's biotech stock picks for 2021. These five have the biggest upside to the posted price targets and are best suited for patient, aggressive growth...
These four sizzling biotech stocks trading under the $10 level could provide investors with some solid upside potential. They are all Buy rated at Goldman Sachs, one of the top firms on Wall Street.
Galapagos was crushed on Wednesday after the firm, in conjunction with Gilead, announced a new commercialization and development agreement for their Rheumatoid Arthritis (RA) treatment.
BioNTech was in the spotlight on Tuesday after it received a sizable price target hike from one key analyst.
Prevail Therapeutics shares absolutely exploded on Tuesday morning after it was announced that the company would be acquired by Eli Lilly.
Alexion Pharmaceutical shares shot up on Monday after it was announced over the weekend that the company would be acquired by AstraZeneca.
CureVac advanced in the fight against COVID-19 by beginning enrollment in its midstage vaccine candidate study. As a result, investors cheered on this news and sent shares higher.
The November 30 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Curis shares are on the run again. This time it’s due to a secondary offering.